This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of smallmolecule treatments.
Lead Pharma is a pharmaceuticalcompany focusing on the discovery and development of innovative medicines for the treatment of immune diseases and cancer. About Lead Pharma.
While large pharmaceuticalcompanies have data on thousands or even millions of compounds, this data is rarely shared due to intellectual property concerns. Data from 21 million molecules and more than 40,000 assays was securely combined into a multitask model. For classification models, the participants reported a median 2.5-7.5%
Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceuticalcompanies. There, I supported AI-enabled DD efforts in their smallmolecule portfolio.
The major hurdles that pharmaceuticalcompanies face are long lead times, high costs and a low probability of success (PoS). Drugs that were developed and commercialised 30+ years ago were relatively simple smallmolecules. Clinical bioinformatics desiderata for Molecular Tumor Boards.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content